Drawing for GPCR THERAPEUTICS

USPTO serial 88122890

GPCR THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
PATEL, SAMIR RAMESH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GPCR THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tracy A. Stitt

Tracy A. Stitt JONES DAY250 VESEY STREETNEW YORK, NY 10281-1047UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for the treatment of cancer; Biological preparations for the treatment of cancerACTIVE—
010Medical diagnostic apparatus for detecting cancerACTIVE—
042Biological, medical, and scientific research in the field of cancer research, diagnosis, and treatment; Scientific research and development in the biological, medical, health care, or pharmacological fields; Clinical and pharmacological research and testing services performed in conjunction with clinical trials; Scientific research and development services in the fields of biotechnology, new drug development, pharmacological formulation, and microbiological research; Scientific research consultation and information services in the biological, medical, health care, or pharmacological fields; Information technology management consultation and new product development services in the biological, medical, health care, or pharmacological fieldsACTIVE—
044Clinical and medical testing for medical diagnostic purposes; Medical testing for diagnostic purposes of reagents, clinical and non-clinical samples, nucleic acids, proteins, and pharmacological formulationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 31, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 30, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 28, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 27, 2021EX5GSOU EXTENSION 5 GRANTED—
Oct 22, 2021EXT5SOU EXTENSION 5 FILED—
Oct 22, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 27, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 23, 2021EX4GSOU EXTENSION 4 GRANTED—
Apr 23, 2021EXT4SOU EXTENSION 4 FILED—
Apr 23, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 9, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 7, 2020EX3GSOU EXTENSION 3 GRANTED—
Oct 7, 2020EXT3SOU EXTENSION 3 FILED—
Oct 7, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 3, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 1, 2020EX2GSOU EXTENSION 2 GRANTED—
Apr 1, 2020EXT2SOU EXTENSION 2 FILED—
Apr 1, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 8, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 4, 2019EX1GSOU EXTENSION 1 GRANTED—
Oct 4, 2019EXT1SOU EXTENSION 1 FILED—
Oct 4, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 8, 2019NOACCORRECTED NOA E-MAILED—
May 7, 2019ICNANOTICE OF ALLOWANCE CORRECTION ENTERED—
May 7, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 24, 2019EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Apr 23, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 26, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 26, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 6, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 17, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 17, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 17, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 16, 2019ALIEASSIGNED TO LIE—
Jan 10, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 10, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 3, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 1, 2019DOCKASSIGNED TO EXAMINER—
Sep 26, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Sep 25, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 22, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance